Negara: Irlandia
Bahasa: Inggris
Sumber: HPRA (Health Products Regulatory Authority)
CEFRADINE
Bristol-Myers Squibb Pharmaceuticals Ltd
500 Milligram
Pdr for Soln Inj/Inf
1981-05-08
PART II SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Velosef for Injection 500 mg 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each vial contains 500 mg cefradine. For excipients, see section 6.1. 3 PHARMACEUTICAL FORM Powder for solution for injection or infusion A white to off-white, free-flowing powder. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS The treatment of infections of the urinary, respiratory tracts and of the skin and soft tissues, bones and joints; also septicaemia and endocarditis. These include: Upper respiratory infections: pharyngitis, sinusitis, otitis media, tonsillitis, laryngo-tracheo bronchitis. Lower respiratory infections acute and chronic bronchitis, lobar and bronchopneumonia. Urinary tract infections: cystitis, urethritis, pyelonephritis. Skin and soft tissue infections: abscess, cellulitis, furunculosis, impetigo. Velosef has been shown to be effective in reducing the incidence of postoperative infections in patients undergoing surgical procedures associated with a high risk of infection. It is also of value where post operative infection would be disastrous and where patients have a reduced host resistance to bacterial infection. Protection is best ensured by achieving adequate local tissue concentrations at the time contamination is likely to occur. Thus, Velosef should be administered immediately prior to surgery and continued during the postoperative period. Bacteriological studies to determine the causative organisms and their sensitivity to Velosef should be performed. Therapy may be instituted prior to receiving the results of the sensitivity test. Sterile Velosef for injection is indicated primarily for those patients unable to tolerate oral medication. It is also indicated for intravenous use either by direct injection or by i Baca dokumen lengkapnya